Massachusetts General Hospital
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220071
- Received
- $57,360,407 in 2,285 records, 2020 ($9,420,870 general, $47,939,537 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: MASSACHUSETTS GENERAL HOSPITAL (THE) Fuzzy (name and state)
- Business registration: The Massachusetts General Hospital Fuzzy (name and state)
- Business registration: THE MASSACHUSETTS GENERAL HOSPITAL INC. Fuzzy (name and state)
- Business registration: THE MASSACHUSETTS GENERAL HOSPITAL INC. Fuzzy (name and state)
- Nonprofit contractor: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: MASSACHUSETTS GENERAL HOSPITAL, THE Fuzzy (name and state)
- Nonprofit: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Patent assignee: MASSACHUSETTS GENERAL HOSPITAL Fuzzy (name and state)
- Trademark owner: MASSACHUSETTS GENERAL HOSPITAL, THE Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 391 | $9,420,870 |
| 2020 | Research payment | 1,894 | $47,939,537 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,894 | $47,939,537 |
| Royalty or License | 140 | $5,881,702 |
| Grant | 31 | $1,415,971 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 67 | $801,072 |
| Gift | 70 | $438,775 |
| Education | 41 | $403,059 |
| Consulting Fee | 17 | $373,780 |
| Space rental or facility fees (teaching hospital only) | 18 | $82,850 |
| Charitable Contribution | 7 | $23,660 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Haemonetics Corporation | $32,200 | Research payment | In-kind items and services | TEG Device, Devices | Utilization of Thromboelastography to Predict Arterial Thromboembolic Events in Revascularized Trauma and Peripheral Vas | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $29,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $26,295 | Research payment | Cash or cash equivalent | AI Rad Companion investigation | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $22,203 | Research payment | Cash or cash equivalent | MAGNETOM Skyra Device, MR - MRI | MGH2012MR6000wald | 2020 |
| 2020-12-31 | Haemonetics Corporation | $19,320 | Research payment | In-kind items and services | TEG Device, Devices | Utilization of Thromboelastography to Predict Arterial Thromboembolic Events in Revascularized Trauma and Peripheral Vas | 2020 |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $18,790 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $18,729 | Research payment | Cash or cash equivalent | syngo X Workplace Device, AT - Fixed interventional x-ray/angiography fluoroscopy | MGH Patel Neurosurgery Clinical AT | 2020 |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $16,857 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $15,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Roche Diagnostics Operations, Inc. | $14,039 | Research payment | Cash or cash equivalent | CD cobas Reagents Device, Centralized Diagnostics | ECH16, RMJ20, RD002376 | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $13,080 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Haemonetics Corporation | $12,000 | Research payment | In-kind items and services | TEG Device, Devices | Utilization of Thromboelastography to Predict Arterial Thromboembolic Events in Revascularized Trauma and Peripheral Vas | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $12,000 | Research payment | Cash or cash equivalent | MGHVan der KouweNeuroClinicalMR | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $10,622 | Research payment | Cash or cash equivalent | MGHSinghIRClinicalCR | 2020 | |
| 2020-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG Device, Devices | Utilization of Thromboelastography to Predict Arterial Thromboembolic Events in Revascularized Trauma and Peripheral Vas | 2020 |
| 2020-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG Device, Devices | Utilization of Thromboelastography to Predict Arterial Thromboembolic Events in Revascularized Trauma and Peripheral Vas | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $9,469 | Research payment | Cash or cash equivalent | Research Fellows in Fast Body MR | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $6,188 | Research payment | Cash or cash equivalent | MGH2019MRIPR932IPR991IPR963Gee | 2020 | |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $6,095 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $6,000 | Research payment | Cash or cash equivalent | MGH2018MRIPR818KWu | 2020 | |
| 2020-12-31 | Edwards Lifesciences Corporation | $5,978 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $5,250 | Research payment | Cash or cash equivalent | MGHHuangNeuroClinicalMR | 2020 | |
| 2020-12-31 | Medline Industries LP | $5,100 | Research payment | Cash or cash equivalent | 4 ART Cartridges | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $4,324 | Research payment | Cash or cash equivalent | MGHPolimeni7TNeuroMR2020 | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3,938 | Research payment | In-kind items and services | FASENRA Drug, Respiratory | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizuma | 2020 |
| 2020-12-31 | Stryker Corporation | $3,920 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,912 | Research payment | Cash or cash equivalent | MGH2014MRIPR900LausanneBrainImagingPolimeni | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,662 | Research payment | Cash or cash equivalent | MGH2020MRIPR926Mojtahed | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,200 | Research payment | Cash or cash equivalent | MGH2011MR0500Andronesi | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,000 | Research payment | Cash or cash equivalent | teamplay images investigation | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,680 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,500 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,438 | Research payment | Cash or cash equivalent | MAGNETOM Prisma Device, MR - MRI | MGHNguyenCardioClinicalMR | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,281 | Research payment | Cash or cash equivalent | MGHGhoshhajraCardiacClinicalCT | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,063 | Research payment | Cash or cash equivalent | MGH2018MRIPR992991Montesi | 2020 | |
| 2020-12-31 | Masimo Corporation | $2,036 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,875 | Research payment | Cash or cash equivalent | MGH2019MRIPR1007Polimeni | 2020 | |
| 2020-12-31 | Medartis Inc. | $1,761 | Gift | In-kind items and services | APTUS Device, ORTHO | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,707 | Research payment | Cash or cash equivalent | MGH2020MRIPR991992Montesi | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,688 | Research payment | Cash or cash equivalent | MGH2019MRIPR899Hadjikhani | 2020 | |
| 2020-12-31 | Masimo Corporation | $1,685 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,464 | Research payment | Cash or cash equivalent | MGH2020MRIPR932963991Gee | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,277 | Research payment | Cash or cash equivalent | MGH2019MRIPR992Harisinghani | 2020 | |
| 2020-12-31 | bioMerieux Inc | $787 | Gift | In-kind items and services | MINIVIDAS Device, Diagnostics | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | MGH2019MRIPR917Nguyen | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | MGH2018MR3200Catana | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $655 | Research payment | Cash or cash equivalent | MGH2020MRIPR963991Gee | 2020 | |
| 2020-12-31 | Masimo Corporation | $594 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $588 | Research payment | Cash or cash equivalent | MGH2020MRIPR9251099Williams | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $469 | Research payment | Cash or cash equivalent | MGH2017MRIPR911Kirsch | 2020 | |
| 2020-12-31 | Allergan, Inc. | $450 | Research payment | In-kind items and services | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $413 | Research payment | Cash or cash equivalent | MGH2018MRIPR963996Catalano | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $407 | Research payment | Cash or cash equivalent | MGH2020MRIPR8591323Ratai | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $375 | Research payment | Cash or cash equivalent | MGH2019MRIPR1080Polimeni | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $350 | Research payment | Cash or cash equivalent | MGH2017MRIPR992991Montesi | 2020 | |
| 2020-12-31 | Masimo Corporation | $321 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $283 | Research payment | Cash or cash equivalent | MGH2020MRIPR925Polimeni | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $167 | Research payment | Cash or cash equivalent | MGH2018MRIPR1105Polimeni | 2020 | |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $149 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-12-31 | Masimo Corporation | $24 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Aimmune Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-30 | KCI USA, Inc. | $150,000 | Royalty or License | Cash or cash equivalent | CELLUTOME Device, DEVICES | 2020 | |
| 2020-12-30 | KCI USA, Inc. | $150,000 | Royalty or License | Cash or cash equivalent | CELLUTOME Device, DEVICES | 2020 | |
| 2020-12-30 | Clinisys, Inc. | $37,697 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-30 | ABBVIE INC. | $1,634 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-997 | 2020 |
| 2020-12-30 | Penumbra, Inc. | $1,462 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SURF | 2020 |
| 2020-12-29 | Incyte Corporation | $68,689 | Research payment | Cash or cash equivalent | A Phase II trial of INCMGA00012 in patients with previously treated advanced or metastatic adenosquamous pancreatic canc | 2020 | |
| 2020-12-29 | United Therapeutics Corporation | $2,549 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2020 |
| 2020-12-29 | United Therapeutics Corporation | $2,058 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2020 |
| 2020-12-29 | Pacira Pharmaceuticals Incorporated | $1,670 | Research payment | In-kind items and services | EXPAREL Drug, PAIN MANAGEMENT | A PHASE 3, RANDOMIZED, DOUBLE BLINDED, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMA | 2020 |
| 2020-12-28 | Biohaven Pharmaceuticals, Inc. | $30,836 | Research payment | Cash or cash equivalent | A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebella | 2020 | |
| 2020-12-28 | PFIZER INC. | $17,784 | Research payment | Cash or cash equivalent | NEUROSCIENCE RESEARCH UNIT PROJECT | 2020 | |
| 2020-12-28 | PFIZER INC. | $17,783 | Research payment | Cash or cash equivalent | NEUROSCIENCE RESEARCH UNIT PROJECT | 2020 | |
| 2020-12-28 | PFIZER INC. | $17,783 | Research payment | Cash or cash equivalent | NEUROSCIENCE RESEARCH UNIT PROJECT | 2020 | |
| 2020-12-28 | Nihon Kohden America, LLC | $5,819 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-28 | Janssen Research & Development, LLC | $995 | Research payment | Cash or cash equivalent | A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of m | 2020 | |
| 2020-12-24 | Regeneron Pharmaceuticals, Inc. | $3,037 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY IN PEDIATRIC SUBJECTS WITH PEANUT ALLERGY TO | 2020 |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $928 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-23 | Agios Pharmaceuticals, Inc. | $172,920 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | Sponsored Research Agreement | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $7,625 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2020 | |
| 2020-12-23 | Edwards Lifesciences Corporation | $7,371 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $2,389 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-23 | Masimo Corporation | $2,333 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-23 | Masimo Corporation | $919 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-22 | Boston Scientific Corporation | $462,022 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | Neuro AF Study | 2020 |
| 2020-12-22 | Radius Health, Inc. | $176,884 | Research payment | Cash or cash equivalent | Dissecting differences between abaloparatide and teriparatide signaling in bone cells | 2020 | |
| 2020-12-22 | Genentech, Inc. | $154,845 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | TOCILIZUMAB PLUS A SHORT PREDNISONE TAPER FOR GIANT CELL ARTERITIS | 2020 |
| 2020-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $93,696 | Research payment | Cash or cash equivalent | Nexavar Drug, Oncology | 2020 | |
| 2020-12-22 | UCB SA | $72,936 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-22 | Boston Scientific Corporation | $55,353 | Research payment | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | Smartphone based coronary artery disease management | 2020 |
| 2020-12-22 | IRONWOOD PHARMACEUTICALS, INC | $1,831 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $1,095 | Research payment | Cash or cash equivalent | NN9536-4451 | 2020 | |
| 2020-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | $325 | Research payment | Cash or cash equivalent | AN OBSERVATIONAL, NON-INTERVENTIONAL, STUDY OF PATIENTS WITH HEREDITARY ANGIOEDEMA IN THE UNITED STATES AND CANADA (EMPO | 2020 | |
| 2020-12-22 | CSL Behring | $126 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-12-21 | Biogen, Inc. | $138,338 | Research payment | Cash or cash equivalent | Digital Quantitative Measurements in ALS | 2020 | |
| 2020-12-21 | Travere Therapeutics, Inc. | $25,342 | Research payment | Cash or cash equivalent | 024PKAN15004 | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $17,165 | Research payment | Cash or cash equivalent | A randomized, double blind, multicenter, placebo controlled study to evaluate safety and efficacy and tolerability of es | 2020 | |
| 2020-12-21 | Merck Sharp & Dohme LLC | $755 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After I | 2020 |
| 2020-12-18 | W. L. Gore & Associates, Inc. | $3,961 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE CARDIOFORM ASD Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter c | 2020 |
| 2020-12-18 | Medtronic Vascular, Inc. | $2,832 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2020 |
| 2020-12-18 | Medical Device Business Services, Inc. | $1,750 | Research payment | Cash or cash equivalent | A Multi-center, Prospective, Single Arm Study of Patients Undergoing a Two or Three Level ACDF Using ViviGen Cellular Bo | 2020 | |
| 2020-12-18 | W. L. Gore & Associates, Inc. | $1,500 | Research payment | Cash or cash equivalent | Carotid Stent Device, Devices | GORE Carotid Stent Clinical Study for the treatment of carotid artery stenosis in patients at increased risk for adverse | 2020 |
| 2020-12-18 | Medical Device Business Services, Inc. | $962 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-12-18 | Incyte Corporation | $59 | Research payment | Cash or cash equivalent | A Phase II trial of INCMGA00012 in patients with previously treated advanced or metastatic adenosquamous pancreatic canc | 2020 | |
| 2020-12-17 | GW Research Limited | $85,000 | Grant | Cash or cash equivalent | Epidiolex Drug, Neurology | 2020 | |
| 2020-12-17 | ABBVIE INC. | $85,000 | Research payment | Cash or cash equivalent | DEPAKOTE Drug, NEUROSCIENCE | 2020 | |
| 2020-12-17 | Biogen, Inc. | $66,020 | Research payment | Cash or cash equivalent | Clinic and home speech and coordination measurement in spinocerebellar ataxias and multiple system atrophy | 2020 | |
| 2020-12-17 | ABBVIE INC. | $12,471 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-17 | Roche Products Limited | $4,138 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-12-17 | Biohaven Pharmaceuticals, Inc. | $3,430 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in | 2020 | |
| 2020-12-17 | Janssen Research & Development, LLC | $1,755 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Ad | 2020 | |
| 2020-12-17 | ABBVIE INC. | $1,614 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-17 | Abbott Laboratories | $656 | Research payment | Cash or cash equivalent | MitraClip Device, Vascular | Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitr | 2020 |
| 2020-12-16 | ABBVIE INC. | $85,000 | Research payment | Cash or cash equivalent | DEPAKOTE Drug, NEUROSCIENCE | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $13,000 | Research payment | Cash or cash equivalent | MK-5475 Drug, CARDIOVASCULAR | A Study to Assess the Safety, Tolerability, and Pharmacodynamics of Multiple Dose MK-5475 in Participants with Hypoxemia | 2020 |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $7,471 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | AstraZeneca Pharmaceuticals LP | $1,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | Merck Sharp & Dohme LLC | $749 | Research payment | In-kind items and services | MK-8189 Drug, NEUROSCIENCE | A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Parti | 2020 |
| 2020-12-16 | Surmodics, Inc. | $300 | Research payment | Cash or cash equivalent | AVess FIH Device, Drug-Coated Balloon | AVess FIH | 2020 |
| 2020-12-16 | Blueprint Medicines Corporation | $100 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | Biohaven Pharmaceuticals, Inc. | $216,481 | Research payment | Cash or cash equivalent | Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder | 2020 | |
| 2020-12-15 | MITSUBISHI TANABE PHARMA HOLDINGS AMERICA, INC. | $214,884 | Research payment | Cash or cash equivalent | FEASIBILITY AND SENSITIVITY OF A SYMPTOM MONITORING APPLICATION IN REAL TIME (SMART) IN ALS | 2020 | |
| 2020-12-15 | Biohaven Pharmaceuticals, Inc. | $185,436 | Research payment | Cash or cash equivalent | Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder | 2020 | |
| 2020-12-15 | Allergan, Inc. | $47,640 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMI | 2020 | |
| 2020-12-15 | Allergan, Inc. | $45,263 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMI | 2020 | |
| 2020-12-15 | Amgen Inc. | $22,275 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | NIDEK CO., LTD. | $20,000 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | PFIZER INC. | $4,131 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | Abbott Laboratories | $1,116 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-12-15 | Incyte Corporation | $59 | Research payment | Cash or cash equivalent | A Phase II trial of INCMGA00012 in patients with previously treated advanced or metastatic adenosquamous pancreatic canc | 2020 | |
| 2020-12-14 | Biohaven Pharmaceuticals, Inc. | $25,486 | Research payment | Cash or cash equivalent | HEALEY ALS Platform Trial - Regimen B Verdiperstat | 2020 | |
| 2020-12-14 | Zogenix Inc. | $22,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Bayer Healthcare Pharmaceuticals Inc. | $7,500 | Research payment | Cash or cash equivalent | Non-Covered | Bay1002670 Endometriosis Dose finding EU & US JP CN | 2020 |
| 2020-12-14 | EMD Serono, Inc. | $1,690 | Research payment | Cash or cash equivalent | Atacicept Biological, Immunology | A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA N | 2020 |
| 2020-12-14 | Bayer Healthcare Pharmaceuticals Inc. | $689 | Research payment | Cash or cash equivalent | Adempas Drug, Cardio-pulmonary | BAY 63-2521 ph II LVD-assoc.-PH | 2020 |
| 2020-12-14 | EMD Serono, Inc. | $125 | Research payment | Cash or cash equivalent | Atacicept Biological, Immunology | A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA N | 2020 |
| 2020-12-11 | PFIZER INC. | $63,346 | Research payment | In-kind items and services | BAVENCIO Drug, ONCOLOGY | A PHASE 2 TWOGROUP TWOSTAGE OPENLABEL STUDY OF AVELUMAB MSB0010718C IN PATIENTS WITH MSS MSIH AND POLEMUTATED RECURRENT | 2020 |
| 2020-12-11 | PTC Therapeutics, Inc. | $50,000 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | Medtronic Vascular, Inc. | $1,500 | Research payment | Cash or cash equivalent | HeartWare HVAD Device, Ventricular Assist Devices | DT PAS | 2020 |
| 2020-12-10 | Aesculap, Inc. | $114,854 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | E.R. Squibb & Sons, L.L.C. | $50,000 | Research payment | Cash or cash equivalent | Systems Serology Analysis to Define Biomarkers for Check Point Inhibition Melanoma | 2020 | |
| 2020-12-10 | Medical Device Business Services, Inc. | $15,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Abbott Laboratories | $7,500 | Research payment | Cash or cash equivalent | MitraClip Device, Cardiac Arrhythmias and Heart Failure | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2020 |
| 2020-12-10 | Abbott Laboratories | $5,000 | Research payment | Cash or cash equivalent | HeartMate 3 Left Ventricular Dev Device, Cardiac Arrhythmias and Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2020 |
| 2020-12-10 | Medtronic, Inc. | $4,619 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-12-10 | Aesculap, Inc. | $3,125 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $2,865 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $2,014 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,414 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | LivaNova USA, Inc. | $1,137 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2020 |
| 2020-12-10 | Medtronic, Inc. | $1,107 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $987 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYP | 2020 | |
| 2020-12-10 | Aesculap, Inc. | $905 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $852 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $670 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $610 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Medtronic, Inc. | $592 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-12-10 | Aesculap, Inc. | $530 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $213 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $148 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $96 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $80 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $79 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $71 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $70 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $60 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Medtronic, Inc. | $52 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2020 |
| 2020-12-10 | Aesculap, Inc. | $40 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Intuitive Surgical Operations, Inc. | $300,000 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | Optically-Subsampled Optical Coherence Tomography ("OS-OCT") | 2020 |
| 2020-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $14,575 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Stryker Corporation | $4,402 | Royalty or License | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2020 | |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $55 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-12-08 | Novartis Pharmaceuticals Corporation | $19,843 | Consulting Fee | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2020 | |
| 2020-12-08 | Alexion Pharmaceuticals, Inc. | $12,446 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-08 | Alexion Pharmaceuticals, Inc. | $5,058 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-12-08 | ABBVIE INC. | $1,323 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $476 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $476 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $476 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $476 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $476 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $393 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $393 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $393 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $393 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $210 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $110 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $110 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $110 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $82 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
The latest 200 records of 2,285.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments